Drug Prices

340B

It’s Time For Congress To Get 340B Out Of Its Blind Spot

That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B. Read the full article at Forbes
Commentary

Trump Puts Drug Pricing Program Fraudsters on Notice

The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans. One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market. ...
Commentary

Germany Wants Cheaper Drugs—And Americans To Pay The Difference

What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually. The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines. ...
Commentary

Don’t penalize patients for shopping smart on drugs — reward them

Patients shouldn’t be penalized for finding a better deal on their prescriptions. Too often, they are. Those who pay out of pocket for medications — often at lower prices through direct-to-consumer platforms — typically receive no credit toward their health plan’s annual deductible. Higher-priced drugs purchased through an insurer’s preferred ...
Blog

The FTC Is Settling for Lower Drug Prices

The FTC alleged that Express Scripts “artificially inflated the list price of insulin drugs by using anticompetitive and unfair rebating practices, and impaired patients’ access to lower list price products, ultimately shifting the cost of high insulin list prices to vulnerable patients.” This is a big win – and not just for ...
Commentary

Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire

President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Commentary

Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing

President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
Commentary

In the rush to hold insurers to account, don’t forget about hospitals

When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.
Commentary

Open, Competitive Market Will Make Trump’s Health Plan Great

President Trump’s recently released Great Healthcare Plan offers several welcome reforms. It endeavors to put patients first by fostering greater price transparency and taking steps to lower health insurance premiums. Its approach to prescription drug policy is a bit more mixed. Read the op-ed here.
Commentary

CMS Officials Are Undermining Trump’s Push For Affordable Drugs

Officials at the Centers for Medicare and Medicaid Services just undermined President Trump’s efforts to make prescription drugs more affordable. Earlier this week, CMS announced the next 15 medicines that will face price caps under Medicare’s Drug Price “Negotiation” Program, a core component of the Inflation Reduction Act signed into ...
340B

It’s Time For Congress To Get 340B Out Of Its Blind Spot

That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B. Read the full article at Forbes
Commentary

Trump Puts Drug Pricing Program Fraudsters on Notice

The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans. One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market. ...
Commentary

Germany Wants Cheaper Drugs—And Americans To Pay The Difference

What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually. The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines. ...
Commentary

Don’t penalize patients for shopping smart on drugs — reward them

Patients shouldn’t be penalized for finding a better deal on their prescriptions. Too often, they are. Those who pay out of pocket for medications — often at lower prices through direct-to-consumer platforms — typically receive no credit toward their health plan’s annual deductible. Higher-priced drugs purchased through an insurer’s preferred ...
Blog

The FTC Is Settling for Lower Drug Prices

The FTC alleged that Express Scripts “artificially inflated the list price of insulin drugs by using anticompetitive and unfair rebating practices, and impaired patients’ access to lower list price products, ultimately shifting the cost of high insulin list prices to vulnerable patients.” This is a big win – and not just for ...
Commentary

Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire

President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Commentary

Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing

President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
Commentary

In the rush to hold insurers to account, don’t forget about hospitals

When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.
Commentary

Open, Competitive Market Will Make Trump’s Health Plan Great

President Trump’s recently released Great Healthcare Plan offers several welcome reforms. It endeavors to put patients first by fostering greater price transparency and taking steps to lower health insurance premiums. Its approach to prescription drug policy is a bit more mixed. Read the op-ed here.
Commentary

CMS Officials Are Undermining Trump’s Push For Affordable Drugs

Officials at the Centers for Medicare and Medicaid Services just undermined President Trump’s efforts to make prescription drugs more affordable. Earlier this week, CMS announced the next 15 medicines that will face price caps under Medicare’s Drug Price “Negotiation” Program, a core component of the Inflation Reduction Act signed into ...
Scroll to Top